Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock, Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Common Stock, Additional Paid-in Capital [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019									671		9,130,984
Balance at Dec. 31, 2019									$ 1	$ 670,999	$ 1,643,565	$ 104,912,480	$ (94,071,040)	$ 13,156,005
Compensation cost for stock options granted												687,752		687,752
Net loss													(2,947,420)	(2,947,420)
Balance (in shares) at Mar. 31, 2020									671		9,130,984
Balance at Mar. 31, 2020									$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Balance (in shares) at Dec. 31, 2019									671		9,130,984
Balance at Dec. 31, 2019									$ 1	670,999	$ 1,643,565	104,912,480	(94,071,040)	13,156,005
Net loss														$ (10,344,633)
Conversion of Series B convertible preferred stock to common stock (in shares)								(48)
Common stock issued for option exercises (in shares)														225,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)														225,000
Balance (in shares) at Sep. 30, 2020									623		10,464,250
Balance at Sep. 30, 2020									$ 1	622,999	$ 1,883,553	111,780,197	(104,415,673)	$ 9,871,077
Balance (in shares) at Mar. 31, 2020									671		9,130,984
Balance at Mar. 31, 2020									$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Compensation cost for stock options granted												1,036,484		1,036,484
Net loss													(3,906,142)	(3,906,142)
Issuance of common stock, net of issuance costs (in shares)											160,108
Issuance of common stock, net of issuance costs											$ 28,820	318,807		347,627
Conversion of Series B convertible preferred stock to common stock (in shares)				(45)		12,786
Conversion of Series B convertible preferred stock to common stock					$ (45,000)	$ 2,301	$ 42,699
Balance (in shares) at Jun. 30, 2020									626		9,303,878
Balance at Jun. 30, 2020									$ 1	625,999	$ 1,674,686	106,998,222	(100,924,602)	8,374,306
Compensation cost for stock options granted												663,593		663,593
Net loss													(3,491,071)	(3,491,071)
Issuance of common stock, net of issuance costs (in shares)											1,083,531
Issuance of common stock, net of issuance costs											$ 195,036	4,143,635		$ 4,338,671
Conversion of Series B convertible preferred stock to common stock (in shares)								(3)	(3)		853
Conversion of Series B convertible preferred stock to common stock										(3,000)	$ 154	2,846
Common stock issued for option exercises (in shares)											225,000			225,000
Common stock issued for option exercises											$ 40,500	500,600		$ 541,100
Shares withheld related to cashless exercise of options and taxes (in shares)											(149,012)
Shares withheld related to cashless exercise of options and taxes											$ (26,823)	(528,699)		$ (555,522)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											225,000			225,000
Common stock issued for option exercise											$ 40,500	500,600		$ 541,100
Balance (in shares) at Sep. 30, 2020									623		10,464,250
Balance at Sep. 30, 2020									$ 1	622,999	$ 1,883,553	111,780,197	(104,415,673)	9,871,077
Balance (in shares) at Dec. 31, 2020									621		47,548,835
Balance at Dec. 31, 2020	$ 9,731,714	$ 3,271,361	$ 13,003,075						$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Compensation cost for stock options granted												639,751		639,751
Net loss													(3,538,069)	(3,538,069)
Conversion of Series B convertible preferred stock to common stock (in shares)				(1)		285
Conversion of Series B convertible preferred stock to common stock					(1,000)	$ 51	949
Issuance of common stock and warrants, net of issuance costs (in shares)											41,211,100
Issuance of common stock and warrants, net of issuance costs											$ 7,417,998	62,250,410		69,668,408
Issuance of common stock upon warrant exercise (in shares)											32,064,148
Issuance of common stock upon warrant exercise											$ 5,771,547	26,988,755		32,760,302
Balance (in shares) at Mar. 31, 2021									620		120,824,368
Balance at Mar. 31, 2021									$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Balance (in shares) at Dec. 31, 2020									621		47,548,835
Balance at Dec. 31, 2020	$ 9,731,714	$ 3,271,361	$ 13,003,075						$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Net loss														$ (15,774,462)
Conversion of Series B convertible preferred stock to common stock (in shares)								(37)
Common stock issued for option exercises (in shares)														699,410
Issuance of common stock upon warrant exercise (in shares)														37,452,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)														699,410
Balance (in shares) at Sep. 30, 2021									584		126,623,541
Balance at Sep. 30, 2021									$ 1	583,999	$ 22,792,225	242,373,694	(124,402,093)	$ 141,347,826
Balance (in shares) at Mar. 31, 2021									620		120,824,368
Balance at Mar. 31, 2021									$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Compensation cost for stock options granted												1,214,110		1,214,110
Net loss													(7,039,248)	(7,039,248)
Conversion of Series B convertible preferred stock to common stock (in shares)				(33)		9,377
Conversion of Series B convertible preferred stock to common stock					$ (33,000)	$ 1,688	$ 31,312
Issuance of common stock upon warrant exercise (in shares)											5,091,351
Issuance of common stock upon warrant exercise											$ 916,443	9,279,198		10,195,641
Balance (in shares) at Jun. 30, 2021									587		125,925,096
Balance at Jun. 30, 2021									$ 1	586,999	$ 22,666,505	240,023,345	(119,204,948)	144,071,902
Compensation cost for stock options granted												1,794,138		1,794,138
Net loss													(5,197,145)	$ (5,197,145)
Conversion of Series B convertible preferred stock to common stock (in shares)								(3)	(3)		854
Conversion of Series B convertible preferred stock to common stock										(3,000)	$ 154	2,846
Common stock issued for option exercises (in shares)											699,410			699,410
Common stock issued for option exercises											$ 125,894	1,596,679		$ 1,722,573
Shares withheld related to cashless exercise of options and taxes (in shares)											(297,829)
Shares withheld related to cashless exercise of options and taxes											$ (53,610)	(1,852,498)		(1,906,108)
Issuance of common stock and warrants, net of issuance costs											$ 296,010	809,184		$ 862,466
Issuance of common stock upon warrant exercise (in shares)														296,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											699,410			699,410
Common stock issued for option exercise											$ 125,894	1,596,679		$ 1,722,573
Balance (in shares) at Sep. 30, 2021									584		126,623,541
Balance at Sep. 30, 2021									$ 1	$ 583,999	$ 22,792,225	$ 242,373,694	$ (124,402,093)	$ 141,347,826